Who
Ken Herrmann
Director
Company insider
Files Form 4 as: Director, Aktis Oncology.
In numbers
- Trades disclosed
- 18
- Buys
- 0
- Sells
- 2
- Bought
- $0
- Sold
- $393K
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 17 Jul 2026
- Last trade
- 20 Jul 2026
- Last filed
- 21 Jul 2026
Companies traded
Activity over time
1 Jul – 1 Oct
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Jul 2026filed 21 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code M | $2803,506 at $0.08 | filing |
| 20 Jul 2026filed 21 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code M | $2,5791,350 at $1.91 | filing |
| 20 Jul 2026filed 21 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $86K3,506 at $24.56 | filing |
| 20 Jul 2026filed 21 Jul 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,506 at $0.00 | filing |
| 20 Jul 2026filed 21 Jul 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,350 at $0.00 | filing |
| 20 Jul 2026filed 21 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $33K1,350 at $24.56 | filing |
| 20 Jul 2026filed 21 Jul 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,506 at $0.00 | filing |
| 20 Jul 2026filed 21 Jul 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,350 at $0.00 | filing |
| 20 Jul 2026filed 21 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code M | $2803,506 at $0.08 | filing |
| 20 Jul 2026filed 21 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code M | $2,5791,350 at $1.91 | filing |
| 20 Jul 2026filed 21 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $86K3,506 at $24.56 | filing |
| 20 Jul 2026filed 21 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $33K1,350 at $24.56 | filing |
| 17 Jul 2026filed 20 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code M | $2453,065 at $0.08 | filing |
| 17 Jul 2026filed 20 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $77K3,065 at $25.21 | filing |
| 17 Jul 2026filed 20 Jul 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,065 at $0.00 | filing |
| 17 Jul 2026filed 20 Jul 2026 | AKTS Aktis Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code M | —3,065 at $0.00 | filing |
| 17 Jul 2026filed 20 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Code M | $2453,065 at $0.08 | filing |
| 17 Jul 2026filed 20 Jul 2026 | AKTS Aktis OncologyBiotechnology | SEC FORM 4 Sold | $77K3,065 at $25.21 | filing |
News
PTC Therapeutics (NASDAQ:PTCT) & Aktis Oncology (NASDAQ:AKTS) Head to Head ContrastAKTS · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Ken Herrmann; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.